List view / Grid view
Opdivo® (nivolumab) has been approved by the European Commission for…
Opdivo® (nivolumab) has been approved by the European Commission for gastric, gastroesophageal junction (GEJ), or oesophageal adenocarcinoma.
The European Commission approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for…
The European Commission approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for certain metastatic colorectal cancers after a trial found the combination meaningfully improved response rates.
The European Commission has approved Opdivo (nivolumab) to treat oesophageal…
The European Commission has approved Opdivo (nivolumab) to treat oesophageal squamous cell carcinoma after studies showed its clinical benefits compared to chemotherapy alone.
